Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Cerebrovascular Diseases(Electronic Edition) ›› 2022, Vol. 16 ›› Issue (01): 12-16. doi: 10.11817/j.issn.1673-9248.2022.01.003

• Expert Forum • Previous Articles     Next Articles

Progress in antithrombotic strategy for atrial fibrillation in patients with cerebral microbleeds

Yao Yu1, Huajun Li1, Yongjie Li1,()   

  1. 1. Department of Neurology, Peking University People's Hospital, Beijing 100044, China
  • Received:2022-01-04 Online:2022-02-01 Published:2022-03-07
  • Contact: Yongjie Li

Abstract:

Cerebral microbleeds (CMBs) are caused by cerebral small vessel diseases with high prevalence. Emerging evidence shows that CMBs are an independent risk factor of intracranial hemorrhage and hemorrhagic transformation after ischemic stroke. Hemorrhage is the biggest concern of antithrombotic therapy. Therefore, antithrombotic therapy is one of the major challenges for atrial fibrillation in patients with CMBs. However, so far there is no high-quality clinical randomized controlled trial to evaluate the benefits and risks of the patients taking antithrombotic therapy. This article reviews the relevant studies to provide evidence for clinicians to antithrombotic strategy according to the clinical characteristics of patients, so as to maximize the benefits of patients.

Key words: Cerebral hemorrhage, Atrial fibrillation, Antithrombotic therapy, Cerebral microbleeds

京ICP 备07035254号-20
Copyright © Chinese Journal of Cerebrovascular Diseases(Electronic Edition), All Rights Reserved.
Tel: 01082266456, 15611963912, 15611963911 E-mail: zhnxgbzzbysy@163.com
Powered by Beijing Magtech Co. Ltd